Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TNO155 is a protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; src homology region 2 domain phosphatase; PTPN11) inhibitor(IC50 : 0.011 μM),with potential antineoplastic activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 91.00 | |
2 mg | In stock | $ 129.00 | |
5 mg | In stock | $ 216.00 | |
10 mg | In stock | $ 322.00 | |
25 mg | In stock | $ 547.00 | |
50 mg | In stock | $ 788.00 | |
100 mg | In stock | $ 1,080.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 238.00 |
Description | TNO155 is a protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; src homology region 2 domain phosphatase; PTPN11) inhibitor(IC50 : 0.011 μM),with potential antineoplastic activity. |
Targets&IC50 | SHP2:0.011 µM |
Synonyms | Batoprotafib |
Molecular Weight | 421.95 |
Formula | C18H24ClN7OS |
CAS No. | 1801765-04-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 185 mg/mL (438.44 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TNO155 1801765-04-7 Metabolism Phosphatase Aberrant BCS NSCLC Batoprotafib SHP2 TNO 155 Inhibitor malignancy CRC inhibit allosteric TNO-155 EGFR-mutant RTK-dependent HNSCC activation inhibitor